April 17, 2026

Claritev Corporation (CTEV) Stock Analysis: Exploring a Potential 117% Upside in Healthcare Tech

Claritev Corporation (NASDAQ: CTEV) presents an intriguing opportunity for investors looking to capitalize on the healthcare technology sector. With a market capitalization of $333.4 million, this McLean, Virginia-based company is..

Cel-Sci Corporation (CVM) Stock Analysis: Exploring a 438.79% Potential Upside in Biotech

For investors keen on exploring opportunities within the biotechnology sector, Cel-Sci Corporation (CVM) presents a fascinating case. Headquartered in Vienna, Virginia, and trading on the American exchange, this clinical-stage biotech..

Tectonic Therapeutic, Inc. (TECX) Stock Analysis: A Biotech with 162% Potential Upside

Tectonic Therapeutic, Inc. (NASDAQ: TECX) is making waves in the biotechnology sector with a robust focus on developing therapeutic proteins and antibodies aimed at modulating G protein-coupled receptors (GPCRs). Headquartered..

SI-BONE, Inc. (SIBN) Stock Analysis: Potential 90% Upside in the Medical Device Sector

SI-BONE, Inc. (NASDAQ: SIBN), a pivotal player in the medical device industry, has garnered attention for its innovative biomechanical solutions aimed at addressing compromised bone conditions. Headquartered in Santa Clara,..

Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: Exploring a 105% Upside Potential Amid Biotech Innovations

Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) stands at the forefront of the biotechnology sector, boasting an impressive market capitalization of $1.15 billion. Specializing in the development of innovative therapies designed to..

Inventiva S.A. (IVA): Analyst Ratings Reveal 168% Upside Potential in Biotech Sector

Investors keeping an eye on the biotech sector may want to consider Inventiva S.A. (IVA), a France-based clinical-stage biopharmaceutical company that is currently making waves with its promising developments in..

Cullinan Therapeutics, Inc. (CGEM) Investor Outlook: Analyzing the 112.72% Potential Upside

Cullinan Therapeutics, Inc. (NASDAQ: CGEM) is making waves in the biotechnology sector with its promising pipeline of therapies targeting autoimmune diseases and cancer. The clinical-stage biopharmaceutical company, based in Cambridge,..

Butterfly Network, Inc. (BFLY) Stock Analysis: Riding the Wave of 41% Revenue Growth in the Medical Devices Sector

Butterfly Network, Inc. (NASDAQ: BFLY), a promising player in the medical devices industry, is generating significant interest among investors, particularly due to its outstanding 41% revenue growth. This U.S.-based company..

EyePoint, Inc. (EYPT) Stock Analysis: Unpacking a 150% Potential Upside in the Booming Biotech Sector

EyePoint, Inc. (NASDAQ: EYPT) is capturing investor attention with a remarkable potential upside of 150.96%, according to current analyst ratings. As a key player in the healthcare sector, specifically within..

CorMedix Inc. (CRMD) Stock Analysis: A Biotech with 104% Potential Upside

For investors eyeing the healthcare sector, particularly within biotechnology, CorMedix Inc. (NASDAQ: CRMD) presents an intriguing opportunity. This Parsippany, New Jersey-based biopharmaceutical company is in the spotlight due to its..

Organogenesis Holdings Inc. (ORGO): Investor Outlook with a 213% Potential Upside

Organogenesis Holdings Inc. (NASDAQ: ORGO), a key player in the regenerative medicine sector, has captured investor attention with its robust revenue growth and significant potential upside. The company, which operates..

Cross Country Healthcare, Inc. (CCRN) Stock Analysis: Navigating a 17.96% Potential Upside in the Healthcare Sector

Cross Country Healthcare, Inc. (NASDAQ: CCRN), a key player in the healthcare staffing industry, offers a range of talent management services across the United States. With a market capitalization of..

AnaptysBio, Inc. (ANAB) Investor Outlook: Unveiling a 19.45% Potential Upside in the Biotech Arena

AnaptysBio, Inc. (NASDAQ: ANAB), a prominent player in the biotechnology sector, is making waves with its promising pipeline of immunology therapeutics. With a market capitalization of $1.92 billion, this clinical-stage..

Avanos Medical, Inc. (AVNS) Stock Analysis: Riding the Wave with a 52-Week High and Strategic Growth in Medical Devices

Avanos Medical, Inc. (NYSE: AVNS) is making waves in the healthcare sector with its robust presence in the medical devices industry. With a market capitalization of $1.15 billion, this Alpharetta,..

Verastem, Inc. (VSTM) Stock Analysis: 158% Potential Upside Sparks Investor Interest

Verastem, Inc. (NASDAQ: VSTM), a biopharmaceutical company specializing in cancer treatment, is attracting attention from investors due to its significant upside potential. With a market capitalization of approximately $556.92 million,..

Pharvaris N.V. (PHVS) Stock Analysis: Exploring a 62.93% Upside Potential in the Biotech Sector

Pharvaris N.V. (NASDAQ: PHVS) stands out in the healthcare sector as a biotechnology firm focused on addressing rare diseases with a significant unmet need. With a current market capitalization of..

Theravance Biopharma, Inc. (TBPH) Stock Analysis: Impressive Revenue Growth and Strategic Collaborations Signal Potential Upside

Theravance Biopharma, Inc. (NASDAQ: TBPH) stands out in the competitive biotechnology sector with its focus on developing and commercializing innovative medicines in the United States. With a market capitalization of..

Sana Biotechnology, Inc. (SANA) Stock Analysis: A Promising 147% Potential Upside in the Biotech Sector

Sana Biotechnology, Inc. (NASDAQ: SANA), a pioneering player in the biotech industry, is capturing investor attention with its robust potential upside of 147.02%. Specializing in cutting-edge cell engineering platforms, Sana..

Tilray Brands, Inc. (TLRY) Investor Outlook: Potential Upside of Nearly 48% Amid Diverse Product Portfolio

Tilray Brands, Inc. (NASDAQ: TLRY), a prominent player in the healthcare sector and a leader in the drug manufacturing industry, is a focal point for investors seeking promising opportunities within..

Xencor, Inc. (XNCR) Stock Analysis: Exploring a 128% Potential Upside in Biotech Innovation

For investors with a keen interest in the biotechnology sector, Xencor, Inc. (NASDAQ: XNCR) presents a compelling opportunity, offering an impressive 128.25% potential upside according to analyst ratings. This clinical-stage..

Search

Funds

April 17, 2026

Search

Funds

April 17, 2026

FTSE 100

Funds